Abstract
Despite a number of effective pharmaceutical options for the prevention and treatment of the pathophysiologic responses that occur in sensitized patients on allergen exposure, the termination of allergic hypersensitivities remains an elusive therapeutic goal. Traditional immunotherapy with allergen extracts is the only currently used intervention that has been shown to induce allergen tolerance, but it has a limited scope of efficacy. However, recent studies suggest that immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) –based interventions might offer an alternative and potentially more effective means for extinguishing TH2-biased hypersensitivities. Three basic ISS-ODN – based immunotherapeutic strategies have been studied to date. Immunization with allergen mixed with ISS- ODN, immunization with allergen –ISS- ODN conjugates, and immunomodulation with ISS- ODN alone all have proved efficacy in the attenuation of the allergic phenotype in mice. Preliminary results with allergen – ISS- ODN conjugate vaccines in allergic patients have also been encouraging. This article will provide our perspective on the application of ISS-ODN – based vaccination and immunomodulation to the treatment of atopic diseases and the immunologic basis for their antiallergic activities. (J Allergy Clin Immunol 2002;110:706-12.)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
